PRKCB and Nephropathy: A randomized, double-blind, placebo-controlled study assessing the effect of ruboxistaurin, a selective PKC-β inhibitor, for 1 year in type 2 diabetic patients with nephropathy found a renoprotective effect through reducing albuminuria and maintaining GFR for more than 1 year [62].